Arylsulfatase A deficiency

Below you will find more information about Arylsulfatase A deficiency from Medigest. If you believe that you are suffering from any of the symptoms of Arylsulfatase A deficiency it is important that you obtain an accurate diagnosis from a medical professional to ensure that you obtain the correct medication or treatment for your condition. There are medical conditions that carry similar symptoms associated with Arylsulfatase A deficiency and therefore the information provided by Medigest is offered as a guideline only and should never be used in preference to seeking professional medical advice. The information relating to Arylsulfatase A deficiency comes from a third party source and Medigest will not be held liable for any inaccuracies relating to the information shown.

Definition

Arylsulfatase A deficiency also referred to as Metachromatic leukodystrophy (MLD) is the very ordinary type of a family of hereditary ailments identified as the leukodystrophies, ailments that involves the enlargement and/or growth of myelin, the fatty layer which works as an insulator around nerve fibers all through the inner and marginal nervous systems. Arylsulfatase A results to a damaging swelling of fatty material in the body.

Treatment

There is no treatment for MLD or even a normal type of cure. Children with complex juvenile or adult onset and late infantile patients showing symptoms include treatment partially to pain and symptom management. Presymptomatic late infantile MLD patients, in addition to individuals with juvenile or adult MLD that are also presymptomatic or showing gentle to fair symptoms, have the alternative of bone marrow transplantation that includes stem cell transplantation which may delay the development of the ailment, or discontinue its development in the inner nervous system, though consequences in the peripheral nervous system have been less remarkable and the long term involves of these therapies have confirm varied outcomes. Treatment alternatives for the future that are presently being considered comprise gene therapy and enzyme replacement therapy (ERT), substrate reduction therapy (SRT), and potentially an enzyme enhancement therapy (EET). A team of international researchers and foundations has prepared to structure an International MLD Registry to make and deal with a common repository of facts, as well as the natural history of MLD. This group consists of scientific, academic and industry funds. The registry is not up and working as of December, 2007, however the team is hopeful that this will change in 2008.

Symptoms and Signs

Similar to several additional hereditary disorders that concerns lipid metabolism, there are numerous types of MLD, which are late infantile, juvenile, and adult. 1. Late infantile type - which is the most familiar form MLD, affected children start having troubles walking later than the first year of life. Symptoms consist of muscle wasting and failing, muscle stiffness, developmental setbacks, progressive failure of vision resulting to loss of sight, seizures, damaged ingestion, paralysis, and dementia. Children may turn out to be comatose. Untreated, most children with this type of MLD die by the age of 5, regularly a lot earlier. 2. Juvenile type - beginning between 3-10 years of age regularly start by impaired school performance, mental weakening, and dementia and then build up symptoms like to the late infantile type but with slower development. Age of death is inconsistent, but usually within 10 to 15 years of symptom commencement. 3. Adult type - usually starts following the age 16 as a psychiatric disorder or progressive dementia. Adult-onset MLD develops more gradually than the late infantile and juvenile types, with a prolonged course of a decade or more. In unusual cases the body can compensate for the deficit and the person will show no signs.

Causes

MLD is directly caused by a lack of the enzyme arylsulfatase A. Lacking this enzyme, sulfatides increases in several tissues of the body finally tearing down the myelin of the nervous system. Inheritance goes after an autosomal recessive guide.

Discuss Arylsulfatase A deficiency in our forums

Discuss Arylsulfatase A deficiency with other members of Medigest in our forums.